Evidence map›Paper›PMID 34938384›Full record

ArticleOxidative medicine and cellular longevity2021

Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota.

Xiaoting Zhou, Jiachen Lu, Kehong Wei, Jing Wei, Puyuan Tian, Mengyun Yue, Yun Wang, Daojun Hong, Fangjun Li, Bo Wang and 2 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xiaoting ZhouDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Jiachen LuNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.
Kehong WeiNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.
Jing WeiNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.
Puyuan TianNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.
Mengyun YueDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Yun WangDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Daojun HongDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Fangjun LiDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Bo WangDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Tingtao ChenNational Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, China.ORCID https://orcid.org/0000-0002-0506-8536
Xin FangDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.ORCID https://orcid.org/0000-0001-7768-3127
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a common degenerative disease of the central nervous system. Although some drugs can alleviate the progress of PD, their long-term use will lead to complications, so it is still necessary to find new drugs to delay or cure PD effectively. In view of the difficulty in developing new drugs, it is imperative to discover new functions of existing compounds that could be used to treat PD. In this study, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used to induce PD symptoms in a mouse model. Subsequently, these mice were treated with the antibiotic ceftriaxone. Ceftriaxone alleviated the behavioural and neuropathological changes induced by MPTP, downregulated the expression of glial fibrillary acidic protein (GFAP) and ionised calcium-binding adapter molecule 1 (Iba1) as markers of astroglia and microglia, respectively, and reduced the expression of neuroinflammation-related Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), and phosphorylated nuclear factor kappa-B (p-NF-

Indexed as

Gastrointestinal Microbiome1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAnti-Bacterial AgentsCeftriaxoneDisease Models, AnimalIntestinal MucosaMaleMiceMice, Inbred C57BLNeuroinflammatory DiseasesNeuroprotective AgentsNeurotoxinsParkinson Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnti-Bacterial AgentsCeftriaxoneNeuroprotective AgentsNeurotoxins

Identifiers

PMID34938384
PMCPMC8687851
OpenAlexW4200025659

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.